Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), settled the day at a share price of $18.81 after seeing a rise of 1.29% that brought its market cap to $975.11 million. When looking at performance, we see the stock demonstrating a weekly performance of 10.06% while keeping a monthly performance of 16.47%. Quarterly performance saw a drop of -20.45% and continued the negative trend with a yearly performance of -51.28% while showing YTD performance of -20.7% which was -26.92% for last six months. The 52-week range for the stock was 13.12 – 39.10 that put its current price at a premium of 43.37% to the 52-week low price whereas it is trading at a discount of -51.89% to the 52-week high price.
On January 21, 2020, Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), announced that the U.S. Food and Drug Administration (FDA) has found the New Drug Application (NDA) for SPN-812 for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) acceptable for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020. “SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade,” said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “This is critical for the nearly 6.1 million children and adolescents in the U.S. who are diagnosed with the condition and are in need of a treatment that is a non-controlled substance and that works differently from currently available treatments.”
The NDA for SPN-812 is based on data from an extensive development program consisting of four Phase III clinical trials that studied the pediatric patient population from the age of 6 to 17 years, two Phase II clinical trials, several Phase I trials, a long-term open label extension study, preclinical testing, and drug manufacturing data. Each of the four pivotal clinical trials showed a reduction in ADHD-RS-5 total score as early as Week 1 and continuing until the end of the clinical study, as well as improvement in both hyperactivity/impulsivity and inattention subscales. The effect was statistically significant for the studies for 100mg, 200mg, and 400mg doses. SPN-812 had an acceptable safety profile with low incidence of adverse events and low discontinuation rates. In addition, during the fourth quarter of 2019, the Company initiated a Phase III program to study SPN-812 in the adult ADHD patient population.
The Generic Drugs company is currently upholding a gross margin of 95.8% while maintaining a net profit margin of 28.8%. Operating margin for the last 12 months remained 37.8%. The company’s EPS for trailing 12 months is $2.11 and it is estimated to be posting an EPS of $0.27 for the current quarter. The Beta number showed the stock is subject to risk 50% more than the market as a whole. In the trailing twelve months, its return on assets (ROA) is 10.4% while ROE for the same period is 21% and have seen an average of 12.1% return on investment (ROI). The outstanding share count is 51.84 million shares but the size of available float is 50.74 million shares.
The stock’s current price is lagging SMA-200 by -24.58% which is also -3.89% down from SMA-50. Reducing that period to a shorter term, we see the price is trailing 12.94% to the SMA-20. Volatility for the week was 5.42%, which was 9.09% in the previous month. The company closed the session with a trading volume of 491.56 thousand shares, below from its average daily trading volume of 630.38 thousand. It has been generating revenue of $392.8 million while net income posted by the company in last 12 months was $113.1 million.